Expression Pattern of BCCIP in Hepatocellular Carcinoma is Correlated with Poor Prognosis and Enhanced Cell Proliferation

Overview

Journal Tumour Biol

Publisher Sage Publications

Specialty Oncology

Date 2016 Nov 11

PMID 27832471

Citations 5

Authors

Zhipeng Lin

Baoying Hu

Wenkai Ni

Xiaofei Mao

Huiling Zhou

Jiale Lv

Bihui Yin

Zhongyi Shen

Miaomiao Wu

Wensen Ding

Mingbing Xiao

Runzhou Ni

Affiliations

Soon will be listed here.

Abstract

BCCIP was originally identified as a BRCA2- and CDKN1A- (Cip1/waf1/p21) interacting protein, also known as BCCIP. It has been reported to express in various types of cancers, including colorectal cancer (CRC), astrocytic brain tumors, and glioblastomas. However, the relationship between BCCIP expression and clinicopathological features of hepatocellular carcinoma (HCC) remains to be determined. Herein, we demonstrated that BCCIP was downregulated in clinical HCC tissues; its level was inversely correlated with multiple clinicopathological factors, such as tumor grade, tumor size, and Ki67 expression. Cox regression analysis of tumor samples revealed that BCCIP expression status was an independent prognostic factor for HCC patients' poor survival. Our study also indicated that BCCIP shutdown reduces p21 expression and accelerates G1 to S progression of LO2 hepatocytes significantly. Moreover, there is an interaction between BCCIP and p53 in hepatic L02 cells, and the downregulation of p21 expression by BCCIP is in a p53-dependent way. These findings revealed that BCCIP may play a significant role for the determination of HCC progression through its role in regulating cell growth. Thus, our results suggest that BCCIP is of potential interest for prognostic marker and therapeutic target of HCC.

Citing Articles

Regulation of ferroptosis by noncoding RNAs: a novel promise treatment in esophageal squamous cell carcinoma.

Qiao G, Zhang W, Dong K Mol Cell Biochem. 2022; 477(9):2193-2202.

PMID: 35449482 DOI: 10.1007/s11010-022-04441-0.

BCCIP is required for nucleolar recruitment of eIF6 and 12S pre-rRNA production during 60S ribosome biogenesis.

Ye C, Liu B, Lu H, Liu J, Rabson A, Jacinto E Nucleic Acids Res. 2020; 48(22):12817-12832.

PMID: 33245766 PMC: 7736804. DOI: 10.1093/nar/gkaa1114.

The HMGB1-2 Ovarian Cancer Interactome. The Role of HMGB Proteins and Their Interacting Partners MIEN1 and NOP53 in Ovary Cancer and Drug-Response.

Camara-Quilez M, Barreiro-Alonso A, Vizoso-Vazquez A, Rodriguez-Belmonte E, Quindos-Varela M, Lamas-Maceiras M Cancers (Basel). 2020; 12(9).

PMID: 32867128 PMC: 7564582. DOI: 10.3390/cancers12092435.

Spontaneous Development of Hepatocellular Carcinoma and B-Cell Lymphoma in Mosaic and Heterozygous Brca2 and Cdkn1a Interacting Protein Knockout Mice.

Lu H, Ye C, Feng X, Liu J, Bhaumik M, Xia B Am J Pathol. 2020; 190(6):1175-1187.

PMID: 32201259 PMC: 7280756. DOI: 10.1016/j.ajpath.2020.01.020.

Roles of BCCIP deficiency in mammary tumorigenesis.

Droz-Rosario R, Lu H, Liu J, Liu N, Ganesan S, Xia B Breast Cancer Res. 2017; 19(1):115.

PMID: 29047390 PMC: 5648485. DOI: 10.1186/s13058-017-0907-5.

References

Ma X, Han J, Wu Q, Liu H, Shi S, Wang C . Involvement of dysregulated Wip1 in manganese-induced p53 signaling and neuronal apoptosis. Toxicol Lett. 2015; 235(1):17-27. DOI: 10.1016/j.toxlet.2014.12.019. View

Huang Y, Dai L, Gaines D, Droz-Rosario R, Lu H, Liu J . BCCIP suppresses tumor initiation but is required for tumor progression. Cancer Res. 2013; 73(23):7122-33. PMC: 3918420. DOI: 10.1158/0008-5472.CAN-13-1766. View

Lu H, Guo X, Meng X, Liu J, Allen C, Wray J . The BRCA2-interacting protein BCCIP functions in RAD51 and BRCA2 focus formation and homologous recombinational repair. Mol Cell Biol. 2005; 25(5):1949-57. PMC: 549367. DOI: 10.1128/MCB.25.5.1949-1957.2005. View

Meng X, Lu H, Shen Z . BCCIP functions through p53 to regulate the expression of p21Waf1/Cip1. Cell Cycle. 2004; 3(11):1457-62. DOI: 10.4161/cc.3.11.1213. View

Meng X, Liu J, Shen Z . Genomic structure of the human BCCIP gene and its expression in cancer. Gene. 2003; 302(1-2):139-46. DOI: 10.1016/s0378-1119(02)01098-3. View

McShane L, Altman D, Sauerbrei W, Taube S, Gion M, Clark G . REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer. 2005; 93(4):387-91. PMC: 2361579. DOI: 10.1038/sj.bjc.6602678. View

Wan C, Hou S, Ni R, Lv L, Ding Z, Huang X . MIF4G domain containing protein regulates cell cycle and hepatic carcinogenesis by antagonizing CDK2-dependent p27 stability. Oncogene. 2013; 34(2):237-45. DOI: 10.1038/onc.2013.536. View

Meng X, Fan J, Shen Z . Roles of BCCIP in chromosome stability and cytokinesis. Oncogene. 2007; 26(43):6253-60. PMC: 2667889. DOI: 10.1038/sj.onc.1210460. View

Wang F, Fan J, Zhang Z, Gao B, Wang H . The global burden of liver disease: the major impact of China. Hepatology. 2014; 60(6):2099-108. PMC: 4867229. DOI: 10.1002/hep.27406. View

10.

Altekruse S, McGlynn K, Reichman M . Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009; 27(9):1485-91. PMC: 2668555. DOI: 10.1200/JCO.2008.20.7753. View

11.

Meng X, Yue J, Liu Z, Shen Z . Abrogation of the transactivation activity of p53 by BCCIP down-regulation. J Biol Chem. 2006; 282(3):1570-6. PMC: 2679999. DOI: 10.1074/jbc.M607520200. View

12.

Ono T, Kitaura H, Ugai H, Murata T, Yokoyama K, Ariga H . TOK-1, a novel p21Cip1-binding protein that cooperatively enhances p21-dependent inhibitory activity toward CDK2 kinase. J Biol Chem. 2000; 275(40):31145-54. DOI: 10.1074/jbc.M003031200. View

13.

Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre P . Genetic pathways to glioblastoma: a population-based study. Cancer Res. 2004; 64(19):6892-9. DOI: 10.1158/0008-5472.CAN-04-1337. View

14.

Liu X, Cao L, Ni J, Liu N, Zhao X, Wang Y . Differential BCCIP gene expression in primary human ovarian cancer, renal cell carcinoma and colorectal cancer tissues. Int J Oncol. 2013; 43(6):1925-34. DOI: 10.3892/ijo.2013.2124. View

15.

Ittmann M . Chromosome 10 alterations in prostate adenocarcinoma (review). Oncol Rep. 1998; 5(6):1329-35. DOI: 10.3892/or.5.6.1329. View

16.

Merlo A . Genes and pathways driving glioblastomas in humans and murine disease models. Neurosurg Rev. 2003; 26(3):145-58. DOI: 10.1007/s10143-003-0267-8. View

17.

Liu J, Yuan Y, Huan J, Shen Z . Inhibition of breast and brain cancer cell growth by BCCIPalpha, an evolutionarily conserved nuclear protein that interacts with BRCA2. Oncogene. 2001; 20(3):336-45. DOI: 10.1038/sj.onc.1204098. View

18.

Mao N, Zhou Q, Kojic M, Perez-Martin J, Holloman W . Ortholog of BRCA2-interacting protein BCCIP controls morphogenetic responses during DNA replication stress in Ustilago maydis. DNA Repair (Amst). 2007; 6(11):1651-60. PMC: 2696116. DOI: 10.1016/j.dnarep.2007.05.012. View

19.

Liu J, Lu H, Ohgaki H, Merlo A, Shen Z . Alterations of BCCIP, a BRCA2 interacting protein, in astrocytomas. BMC Cancer. 2009; 9:268. PMC: 2736977. DOI: 10.1186/1471-2407-9-268. View

20.

Lu H, Huang Y, Mehrotra S, Droz-Rosario R, Liu J, Bhaumik M . Essential roles of BCCIP in mouse embryonic development and structural stability of chromosomes. PLoS Genet. 2011; 7(9):e1002291. PMC: 3178617. DOI: 10.1371/journal.pgen.1002291. View